Catalys Pacific reports 10.1% stake in Mineralys Therapeutics (MLYS)
Rhea-AI Filing Summary
Mineralys Therapeutics, Inc. received an amended Schedule 13G showing that investment entities affiliated with Catalys Pacific and individual reporting person Brian Taylor Slingsby collectively report beneficial ownership of 8,002,738 shares of common stock, or 10.1% of the class as of December 31, 2025.
The filing states that 7,903,838 shares are held of record by Catalys Pacific Fund, LP, with an additional 98,900 shares underlying stock options exercisable within 60 days of December 31, 2025. All reporting persons report shared voting and dispositive power over these 8,002,738 shares, and no sole voting or dispositive power.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What ownership stake in Mineralys Therapeutics (MLYS) does Catalys Pacific report?
Catalys Pacific-affiliated entities and Brian Taylor Slingsby report beneficial ownership of 8,002,738 Mineralys Therapeutics common shares, representing 10.1% of the class as of December 31, 2025. This includes shares held directly and options exercisable within 60 days.
Who are the reporting persons in the Mineralys Therapeutics (MLYS) Schedule 13G/A?
The reporting persons are Catalys Pacific Fund, LP, Catalys Pacific Fund GP, LP, Catalys Pacific, LLC, and Brian Taylor Slingsby. The entities are organized under Cayman Islands laws, while Slingsby is a U.S. citizen and managing director of Catalys Pacific, LLC.
How was the 10.1% Mineralys Therapeutics (MLYS) ownership calculated?
The 10.1% ownership figure is calculated using 79,139,956 Mineralys common shares outstanding as of November 3, 2025. This share count comes from Mineralys’s Form 10-Q filed November 10, 2025, against which the 8,002,738 beneficially owned shares are measured.